Ranibizumab Approved in EU For Vision Loss Due to Diabetic Macular Edema
The European Medicines Agency (EMEA) has granted
Novartis (Basel, Switzerland) a new, broader indication for
ranibizumab (Lucentis, Genentech) to treat patients with
visual impairment due to diabetic macular edema (DME),
according to a company news release.
The approval was based on data from two Novartis-sponsored
cl...